Immunogenic and Protective Properties of the First Kazakhstan Vaccine against Pandemic Influenza A(H1N1) pdm09 in Ferrets

Kaissar Tabynov; Zhailaubai Kydyrbayev; Abylai Sansyzbay; Berik Khairullin; Sholpan Ryskeldinova; Nurika Assanzhanova; Yerken Kozhamkulov; Dulat Inkarbekov

doi:10.1007/s12250-012-3272-7

December 2012

Kaissar Tabynov, Zhailaubai Kydyrbayev, Abylai Sansyzbay, Berik Khairullin, Sholpan Ryskeldinova, Nurika Assanzhanova, Yerken Kozhamkulov and Dulat Inkarbekov. Immunogenic and Protective Properties of the First Kazakhstan Vaccine against Pandemic Influenza A(H1N1) pdm09 in Ferrets[J]. Virologica Sinica, 2012, 27(6): 345-352. doi: 10.1007/s12250-012-3272-7

Citation: Kaissar Tabynov, Zhailaubai Kydyrbayev, Abylai Sansyzbay, Berik Khairullin, Sholpan Ryskeldinova, Nurika Assanzhanova, Yerken Kozhamkulov, Dulat Inkarbekov. Immunogenic and Protective Properties of the First Kazakhstan Vaccine against Pandemic Influenza A(H1N1) pdm09 in Ferrets .VIROLOGICA SINICA, 2012, 27(6) : 345-352. http://dx.doi.org/10.1007/s12250-012-3272-7

Immunogenic and Protective Properties of the First Kazakhstan Vaccine against Pandemic Influenza А (Н1N1) pdm09 in Ferrets

cstr: 32224.14.s12250-012-3272-7

Research Institute for Biological Safety Problems RIBSP, Gvardeiski 080409 Kazakhstan

通讯作者： Kaissar Tabynov*, tabynov_81@mail.ru;
收稿日期： 2012-07-18
录用日期： 2012-10-16

摘要

This paper presents the results of a pre-clinical study of the immunogenicity and efficacy of an egg-derived, inactivated, whole-virion adjuvanted vaccine (Refluvac?) on ferret models. For this purpose, groups of eight ferrets (6 to 7 months old) were injected with 0.5 mL of vaccine specimens containing 3.75, 7.5 or 15.0 μg of virus hemagglutinin. Administration was intramuscular and given either as a single dose or as two doses 14 days apart. All vaccine specimens manifested immunogenicity in ferrets for single (HI titer, from 51 ± 7 to 160 ± 23) and double (HI titer, from 697 ± 120 to 829 ± 117) administrations. To assess the protective effects of the vaccine, ferrets from the vaccinated and control groups were infected intranasally with pandemic virus А/California/7/09 (Н1N1) pdm09 at a dose of 106 EID50/0.5 mL. Fourteen days post-infection, the ferrets inoculated with single or double vaccines containing 3.75, 7.5 or 15.0 μg of hemagglutinin per dose showed no signs of influenza infection, weight loss, or body temperature rise, and no premature deaths occurred. The number of vaccinated ferrets shedding the virus via the upper airway, as well as the amount of virus shed after infection, was significantly reduced in comparison with animals from the control group. Based on our results, we sug-gest that a single vaccination at a dose of 3.75 or 7.5 μg hemagglutinin be used for Phase I clinical trials.
- Vaccine
- , Pandemic Influenza А (Н1N1) pdm09
- , Immunogenic and Protective Properties
- , Ferrets

Immunogenic and Protective Properties of the First Kazakhstan Vaccine against Pandemic Influenza A(H1N1) pdm09 in Ferrets

Research Institute for Biological Safety Problems (RIBSP), Gvardeiski 080409 Kazakhstan

Corresponding author: Kaissar Tabynov, tabynov_81@mail.ru
Received Date: 18 July 2012
Accepted Date: 16 October 2012

Abstract

This paper presents the results of a pre-clinical study of the immunogenicity and efficacy of an egg-derived, inactivated, whole-virion adjuvanted vaccine (Refluvac?) on ferret models. For this purpose, groups of eight ferrets (6 to 7 months old) were injected with 0.5 mL of vaccine specimens containing 3.75, 7.5 or 15.0 μg of virus hemagglutinin. Administration was intramuscular and given either as a single dose or as two doses 14 days apart. All vaccine specimens manifested immunogenicity in ferrets for single (HI titer, from 51 ± 7 to 160 ± 23) and double (HI titer, from 697 ± 120 to 829 ± 117) administrations. To assess the protective effects of the vaccine, ferrets from the vaccinated and control groups were infected intranasally with pandemic virus А/California/7/09 (Н1N1) pdm09 at a dose of 106 EID50/0.5 mL. Fourteen days post-infection, the ferrets inoculated with single or double vaccines containing 3.75, 7.5 or 15.0 μg of hemagglutinin per dose showed no signs of influenza infection, weight loss, or body temperature rise, and no premature deaths occurred. The number of vaccinated ferrets shedding the virus via the upper airway, as well as the amount of virus shed after infection, was significantly reduced in comparison with animals from the control group. Based on our results, we sug-gest that a single vaccination at a dose of 3.75 or 7.5 μg hemagglutinin be used for Phase I clinical trials.
- Vaccine
- , Pandemic Influenza A (H1N1) pdm09
- , Immunogenic and Protective Properties
- , Ferrets

References
1. Ehrlich H J, Müller M, Fritsch S, et al. 2009. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis, 200(7): 1113-1118.
  doi: 10.1086/599179
2. European Union Health Security Committee (HSC)/Early Warning and Response System (EWRS). 2009. HSC/ EWRS statement on influenza A(H1N1) 2009: target and priority groups for vaccination. http://ec.europa.eu/health/ph_threats/com/Influenza/docs/HSC_EWRS_statement_en.pdf
3. Jain F S, Finelli L, Shaw M W, et al. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med, 360: 2605-2615.
  doi: 10.1056/NEJMoa0903810
4. Johansen K, Nicoll A, Ciancio B C, et al. 2009. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill, 14(41): 19361.
5. Katz J, Hancock K, Veguilla V, et al. 2009. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep, 58: 521-524.
6. Li J, Shao T J, Yu X F, Pan J C, et al. 2012. Molecular evolution of HA gene of the influenza A H1N1 pdm09 strain during the consecutive seasons 2009-2011 in Hangzhou, China: Several immune-escape variants without positively selected sites. J Clin Virol, [Epub ahead of print].
7. Lin J, Zhang J, Dong X, et al. 2006. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet, 368: 991-997.
  doi: 10.1016/S0140-6736(06)69294-5
8. Maher J A, DeStefano J. 2004. The ferret: an animal model to study influenza virus. Lab Anim (NY), 33: 50-53.
  doi: 10.1038/laban1004-50
9. Mamadalyiev S, Nurpeysova A, Khairullin B, et al. 2011. Preclinical Testing of Refluvac®, A vaccine against pandemic influenza A/H1N1v. J Appl Environ Biol Sci, 1(3): 48-53.
10. Ninomiya A, Imai M, Tashiro M, et al. 2007. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine, 25: 3554-3560.
  doi: 10.1016/j.vaccine.2007.01.083
11. Palmer D F, Dowdle W R, Coleman M T, et al. 1975. Advanced laboratory techniques for influenza diagnosis. Immun Ser, 6: 25-45.
12. Pascua P N Q, Song M-S, Lee J H, et al. 2009. Evaluation of the efficacy and cross-protectivity of recent human and swine vaccines against the pandemic (H1N1) 2009 virus infection. PLoS ONE, 4(12): e8431.
  doi: 10.1371/journal.pone.0008431
13. Reed L J, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg, 27: 493-497.
14. Ruat C, Caillet C, Bidaut A, et al. 2008. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol, 82: 2565-2569.
  doi: 10.1128/JVI.01928-07
15. Subbarao K, Luke C. 2007. H5N1 viruses and vaccines. PLoS Pathog, 3(3): e40.
  doi: 10.1371/journal.ppat.0030040
16. Vajo Z, Kosa L, Visontay I, et al. 2007. Inactivated Whole Virus Influenza A (H5N1) Vaccine. Emerg Infect Dis, 13(5): 807-808.
  doi: 10.3201/eid1305.061248
17. WHO. 2010. Pandemic (H1N1) 2009: update 106. http://www.who.int/csr/don/2010_06_25/en/index.html.
18. WHO. 2002. WHO manual on animal influenza diagnosis and surveillance. Geneva: World Health Organization.
19. Wood J M, Schild G C, Newman R W, et al. 1977. An improved single radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand, 5: 237-247.
  doi: 10.1016/S0092-1157(77)80008-5
20. Zimmer S M, Burke D S. 2009. Historical perspective -emergence of influenza A(H1N1) viruses. N Engl J Med, 361: 279-285.
  doi: 10.1056/NEJMra0904322
Proportional views